JBPHF (Jacobio Pharmaceuticals Group Co) Institutional Ownership: 5.79% (As of Jul. 11, 2026)


JBPHF Jacobio Pharmaceuticals Group Co Ltd JBPHF
54 GF Score
Price $0.87
GF Value $0.35
! 6 Warning Signs
View Full Analysis

What is Jacobio Pharmaceuticals Group Co Institutional Ownership?

Jacobio Pharmaceuticals Group Co JBPHF +4.52% 54 Institutional Ownership is 5.79% as of Jul. 11, 2026. GuruFocus rates JBPHF with a GF Score™ of 54/100 and a GF Value™ of $0.35. The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Jacobio Pharmaceuticals Group Co's institutional ownership is 5.79%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Jacobio Pharmaceuticals Group Co's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Jacobio Pharmaceuticals Group Co's Float Percentage Of Total Shares Outstanding is 0.00%.

Jacobio Pharmaceuticals Group Co Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Jacobio Pharmaceuticals Group Co's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jacobio Pharmaceuticals Group Co Institutional Ownership Chart

Jacobio Pharmaceuticals Group Co Historical Data

The historical data trend for Jacobio Pharmaceuticals Group Co can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 1.69 1.90 2.19 4.29 4.26 4.32 4.32 4.13 4.27 4.24
JBPHF
54GF Score
Jacobio Pharmaceuticals Group Co Ltd JBPHF
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jacobio Pharmaceuticals Group Co Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 5.79% mean?
Jacobio Pharmaceuticals Group Co (JBPHF) has a Institutional Ownership of 5.79% as of Jul. 11, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Jacobio Pharmaceuticals Group Co and its competitors.
Is Jacobio Pharmaceuticals Group Co's Institutional Ownership too high?
Jacobio Pharmaceuticals Group Co's current Institutional Ownership is 5.79%. Overall, Jacobio Pharmaceuticals Group Co has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Jacobio Pharmaceuticals Group Co's Institutional Ownership compare to VRTX and REGN?
Jacobio Pharmaceuticals Group Co's Institutional Ownership of 5.79% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. Jacobio Pharmaceuticals Group Co's current Institutional Ownership is 5.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobio Pharmaceuticals Group Co stock overvalued right now?
Jacobio Pharmaceuticals Group Co (JBPHF) has a current Institutional Ownership of 5.79%. The stock's GF Value™ is $0.35, compared to a current price of $0.87 — trading 147.9% above its estimated fair value. The current Institutional Ownership is 5.79%. Jacobio Pharmaceuticals Group Co's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Jacobio Pharmaceuticals Group Co (JBPHF), the current Institutional Ownership is 5.79% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jacobio Pharmaceuticals Group Co (JBPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co stock appears to be overvalued. The current stock price of $0.87 is trading 147.9% above its estimated GF Value™ of $0.35.

Key valuation signals for JBPHF:

  • Institutional Ownership: 5.79%
  • GF Value™: $0.35 vs. price of $0.87 (147.9% above fair value)
  • GF Score™: 54/100 with 6 warning signs

No single metric tells the full story. See the JBPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jacobio Pharmaceuticals Group Co Business Description

Other Exchanges 01167:Hong Kong77V:Germany
Address No.105 Jinghai 3rd Road, Building 8, Beijing Economic-Technological Development Area, Beijing, CHN
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
54GF Score

Get the complete analysis for JBPHF

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.87
Price
$0.35
GF Value